Letters
The catP gene has been found on various bacterial chromosomes and conjugative plasmids as part of the transposable element Tn4451. This transposon is derivative of the Tn6338 that contains six genes, the largest of which, TnpX, is required for the excision of the transposon in both Escherichia coli and C. perfringens (6) . The Tn4451 derivative that lacked the functional TnpX gene was completely stable in both organisms because it had lost mobility as a result of these internal deletions (6) . The finding of catP in N. meningitidis within such a truncated immobile transposon (1) and the possibility of transfer of this type of resistance among highly transformable organisms such as Neisseria spp. are of great concern. Were the transposon to become a stable part of the meningococcal genome, it could potentially be easily exchanged. Interspecies recombination between antibiotic-resistant genes of N. meningitidis and commensal Neisseria spp. has occurred in penicillin-and sulfonamide-resistant meningococci (7) (8) (9) (10) . A similar occurrence may be possible for N. meningitidis chloramphenicol resistance in Africa or other continents where this antibiotic is routinely used for treatment of patients with meningococcal diseases. Studies have not yet demonstrated the clinical significance of chloramphenicol resistance caused by the catP gene in meningococci. However, it is possible that, in developing countries, patients whose illness does not respond to antimicrobial agents may not be detected, or their isolates may not be obtained. Screening a selection of isolates for catP may allow early detection of chloramphenicol-resistant strains. Since detection of increasing chloramphenicol resistance could change recommendations for antimicrobial-drug therapy, surveillance for antimicrobial-drug resistance should be encouraged.
Iron Loading and Disease Surveillance
To the Editor: We read with interest the article by E. D. Weinberg entitled "Iron Loading and Disease Surveillance" (1). Dr. Weinberg proposes routine population screening of iron values by serum ferritin and transferrin saturation tests. Such screening could provide valuable information for epidemiologic, diagnostic, Letters prophylactic, and therapeutic studies of emerging infectious diseases. However, population screening for hereditary hemochromatosis, the example Dr. Weinberg uses to illustrate his proposal, should await additional data (2) (3) (4) . At this time, it is not known how many people with genetic risk or biochemical evidence of iron overload will actually become ill. Therefore, the benefits of screening cannot be weighed against the risks of unnecessary treatment. Moreover, standardized, reliable methods for measuring and diagnosing iron overload are not available.
Without additional data, population screening can actually be detrimental to those at risk for disease. Persons with hereditary hemochromatosis may face discrimination, including difficulties in acquiring health, life, or disability insurance. Already, current blood safety policy makes it difficult for them to donate blood, even though blood donation is unlikely to have negative consequences. In addition, the costs of screening for hemochromatosis are not routinely covered by medical insurance nor has the cost-effectiveness of screening been determined. If routine screening is adopted, tracking of persons who test positive must be developed to ensure that appropriate and continuing followup is provided and patient confidentiality is preserved.
The Centers for Disease Control and Prevention recommends testing for persons who have either a close relative with hemochromatosis or who themselves experience the unexplained symptoms compatible with the disease (severe weakness or fatigue; unexplained joint or abdominal pain) or its later complications (liver disease, diabetes, or heart problems; impotence; infertility; loss of menstrual periods) (2, 5) . Testing to exclude other causes of these medical problems should also be performed. Persons with elevated iron or liver function measures should be monitored by their healthcare provider.
Reply to Dr. Reyes
To the Editor: The article noted that nearly 50 microbial genera contain strains that are more pathogenic in iron-loaded than in normal hosts. The article proposed "routine screening of populations exposed to certain diseases" but not routine screening of populations at large. A few examples of current interest include atherosclerosis (Coxiella and Chlamydia), septicemia (Capnocytophaga), Whipple's disease (Tropheryma), tuberculosis (Mycobacterium), gastric ulcers (Helicobacter), hepatitis (hepatitis C), and AIDS (opportunistic pathogens).
Of course, the tissue or cell localization of iron and the possible pathogen must be considered. For instance, Legionella multiplies in iron-loaded alveolar macrophages but not in plasma. Thus, it would be expected that persons with untreated hemochromatosis with minimal macrophage iron but with high plasma iron would not be at risk for Legionnaires' pneumonia.
